All Articles

In this fourth installment, Dr Moore shares strategies for optimizing abemaciclib treatment through dose escalation and proactive toxicity management. She emphasizes patient education on managing common side effects and highlights the importance of ongoing patient engagement through touchpoints and clear communication to ensure successful treatment outcomes.

In this third installment, Dr Moore shares insights from the TRADE study, which evaluated a dose-escalation strategy for abemaciclib in patients with HR-positive, HER2-negative, high-risk breast cancer. Dr Moore emphasizes the importance of combining TRADE study findings with real-world evidence to refine dose-escalation strategies and improve patient outcomes.

We are pleased to share this comprehensive new resource designed to support meaningful conversations between healthcare providers, patients, and their care partners.

In this second installment, Dr Mayer discusses her insights from the results of the adjuvant TRADE study and how the dose-escalation approach for abemaciclib used in the study can help patients better manage side effects and stay on therapy, ultimately improving outcomes.

In this first installment, Dr Mayer discusses the results of the adjuvant TRADE study and how it was successful in identifying a dose-escalation strategy for abemaciclib that allowed a significant number of patients to reach and maintain the target with very few patients discontinuing therapy.